[立体定向放射治疗多发性脑转移瘤]

[Stereotactic radiotherapy for multiple brain metastases].

作者信息

Xia Huo-Sheng, Han Shou-Yun, Li Ping, Liu Zhi-Chen, Tang Ping-Yuan

机构信息

Department of Radiotherapy, The 309th Clinical Division, Chinese PLA General Hospital, Beijing 100091, P. R. China.

出版信息

Ai Zheng. 2005 Jun;24(6):711-3.

PMID:15946485

Abstract

BACKGROUND & OBJECTIVE: Stereotactic radiotherapy (SRT) has obvious advantages in treating intracranial tumors, but there are few reports about application of SRT to multiple intracranial tumors. This paper summarized the therapy outcome of patients with multiple brain metastases, and evaluated the efficacy and application of SRT.

METHODS

Clinical data of 136 patients with multiple brain metastases received radiotherapy from Jun. 1996 to Dec. 2002 were reviewed. Of the 136 patients, 52(38.2%) received conventional radiotherapy alone (CR group), 84(61.8%) received SRT or SRT plus whole brain radiotherapy (SRT group).

RESULTS

Clinical effective rate, and elimination rate of brain metastases (diameter of > 20 mm) were significantly higher in SRT group than in CR group (96.4% vs. 86.5%, P=0.02; 70.4% vs. 36.0%, P=0.007). Persistent brain edema rate was 8.3% in SRT group, and 9.6% in CR group (P=0.767). Intracranial tumor recurrence rate was 25.0% in SRT group, and 19.4% in CR group (P=0.653). Median survival time was significantly longer in SRT group than in CR group (10.5 months vs. 6.5 months, P=0.014); 1-year survival rate was significantly higher in SRT group than in CR group (40.5% vs. 21.2%, P=0.023).

CONCLUSION

Reasonable application of SRT could improve life quality and treatment outcome of patients with multiple brain metastases, reduce intracranial tumor recurrence and radiation damage, and prolong patients'survival time.

摘要

背景与目的

立体定向放射治疗（SRT）在颅内肿瘤治疗中具有明显优势，但SRT应用于颅内多发肿瘤的报道较少。本文总结了多发脑转移瘤患者的治疗结果，并评估了SRT的疗效及应用情况。

方法

回顾性分析1996年6月至2002年12月期间接受放疗的136例多发脑转移瘤患者的临床资料。其中，52例（38.2%）仅接受常规放疗（CR组），84例（61.8%）接受SRT或SRT联合全脑放疗（SRT组）。

结果

SRT组的临床有效率及脑转移瘤（直径>20 mm）消除率显著高于CR组（96.4%对86.5%，P=0.02；70.4%对36.0%，P=0.007）。SRT组的持续性脑水肿发生率为8.3%，CR组为9.6%（P=0.767）。SRT组的颅内肿瘤复发率为25.0%，CR组为19.4%（P=0.653）。SRT组的中位生存时间显著长于CR组（10.5个月对6.5个月，P=0.014）；SRT组的1年生存率显著高于CR组（40.5%对21.2%，P=0.023）。